VANI
Vivani Medical, Inc.1.4100
+0.0600+4.44%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
102.86MP/E (TTM)
-Basic EPS (TTM)
-0.45Dividend Yield
0%Recent Filings
8-K
Vivani prices $4.5M stock offering
8-K
Q3 loss, funding secured
Vivani Medical reported Q3 2025 net loss of $6.5M, up from $6.0M year-ago, with cash at $4.0M as of September 30 amid $20M YTD burn. Q3 private placement plus October financings yielded ~$25.7M, funding NPM-139 semaglutide implant Phase 1 into H1 2026. Cash lasts into 2027. Cortigent spin-off delayed by government shutdown.
10-Q
Q3 FY2025 results
Vivani Medical posted a Q3 operating loss of $6.7M, up 6.5% y/y, driven by higher R&D in its core biopharma division while neurostimulation expenses ticked lower. Cash burned to $2.6M from $18.4M at year-start, with $17.6M used in operations (derived) and $2.7M raised via private stock sales. Cash lasts into 2027 per MD&A. Biopharma dominates at 90%+ of spend. Diluted EPS holds steady at -$0.11 despite 8% share growth, anti-dilutive. Litigation drags on.
8-K
Vivani prices $15.7M stock offering
Vivani Medical priced a $15.7 million common stock offering on October 26, 2025, including a registered direct sale of 6 million shares at $1.62 each and a concurrent private placement of 3.7 million shares to an entity tied to Chairman Gregg Williams at the same price. This at-the-market deal, led by ThinkEquity, bolsters Vivani's cash for advancing its NanoPortal implant platform in metabolic disease treatments. Directors and officers face a 60-day lock-up. Funds will fuel R&D and operations.
8-K
Vivani withdraws Cortigent spin-off date
Vivani Medical withdrew the October 8, 2025 record date for spinning off its wholly-owned subsidiary Cortigent, which develops neuromodulation brain implants, due to U.S. federal government shutdown delays. The company plans to set a new date soon, with ThinkEquity advising the transaction. This pause risks further setbacks in unlocking Cortigent's value amid ongoing funding challenges.
BIVI
BioVie Inc.
1.43+0.00
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
IBO
Impact BioMedical, Inc.
0.44-0.02
MOVE
Movano Inc.
8.09-0.55
NVNO
enVVeno Medical Corporation
0.32+0.01
RANI
Rani Therapeutics Holdings, Inc
1.44-0.01
TNON
Tenon Medical, Inc.
1.10+0.02
VIVS
VivoSim Labs, Inc.
1.99+0.01
VVOS
Vivos Therapeutics, Inc.
2.02+0.00